Come join us in 25 for the oral abstract session on #irAEs #ACR23 @jhrheumatology https://t.co/M3N9VCLNDb

TM66 at #ACR23 60 yo M w/ worsening PMR symptoms (polyarthralgias, difficulty raising arms) & b/l vision loss PMH: PMR, central serous chorioretinopathy, HTN VS: 100.2 F, HR 108 Labs: - CRP 100 mg/dL, ESR 81 mm/h - UA: proteinuria (100 mg/dL) - ANA > 1:10,000, dsDNA > 300… https://t.co/T7Nov5vyoc https://t.co/3GuXVgh03Z

Treatment of lupus nephritis #ACR23 Dall’Era M, Furie R, Mosca M @RheumNow https://t.co/Md2DsOrY5F

TM61 at #ACR23 23 yo M p/w ~3mo of sternal swelling - US probable abscess, drained + multiple abx w/ no improvement - XR R shoulder + L elbow nl but MRI abn - MRI L elbow: possible osteomyelitis (OM) - MRI R shoulder; clavicular osteolysis - Bone Bx clavicle + L Ulna: Chronic… https://t.co/7s9PIwByTs https://t.co/wKaKfnncP5

#ACR23 Late-Breaking Abstr#L10 Phase 2 crossover RCT of Dazodalibep, in #Sjogren pts with low ESSDAI but high ESSPRI. ESSPRI and FACIT-FATIGUE improved in both Stage 1 and also after X-over after 159 days. One to look out for those with high symptoms burden @RheumNow #ACRBest https://t.co/yGGrPmUOHU

🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases 🫁 🔸 Screening & Monitoring Recs 🔸 Treatment Guidelines ILD/RP-ILD #RheumTwitter #PulmTwitter #MedTwitter #MedX https://t.co/JreVO0kgEf

👨‍⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23 By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ

Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Clinical Year in Review at #ACR23 By @philseo (@jhrheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u

My takeaways from #ACR23 #ReviewCourse session on Inflammatory Eye Disease - Dr. Laura Kopplin: 1. Systemic therapy has better long term outcomes than topical treatments, but many/most ophthalmologists are uncomfortable with prescribing there. 2. FAST Trial: Methotrexate better… https://t.co/eoSeWVHsf0

Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/TnCsgxOfCM https://t.co/HEd4NWnuuX

• Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Y…

Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype.. #Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

Latest in Lupus Treatment at #ACR23 • Dr. Dall’Era & Dr. Furie • Approach to Lupus Nephritis 🫘 • Treating Non-Renal SLE / Skin #Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe

Great time at the Knowledge Bowl! Huge thanks to my co-hosts, judges, and amazing #ACR23 staff Congrats to the IGGenerals for taking home the big prize and kudos to ANA 1:40 for the much deserved spirit award! https://t.co/u7bFeQjXeY